Dermata Therapeutics, Inc. (DRMA) News & Overview - Discounting Cash Flows
DRMA
Dermata Therapeutics, Inc.
DRMA (NASDAQ)

DRMA's Business Model

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Sector & Industry Healthcare / Biotechnology
Website https://www.dermatarx.com
CEO (Chief Executive Officer) Gerald T. Proehl
Number of Employees
IPO date August 13, 2021

DRMA Latest News

Contact
CountryUS
Address3525 Del Mar Heights Road
CitySan Diego
StateCA
Phone858 800 2543
Zip Code92130
Other Identifiers
CIK0001853816
ISINUS2498454055
CUSIP249845108
Open0.66
Previous Close0.695
Volume693.9 Thou.
Average Volume158.1 Thou.
Day’s Range0.6201 – 0.6777
52 Week Range0.574-5
MA (50)0.7369
MA (200)1.11186
Market Cap4.02 Mil.
Shares Out.6.38 Mil.
Earnings DateAug 07, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for DRMA

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us